Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Accumulated Expenses: 2015-2025

Historic Accumulated Expenses for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $6.4 million.

  • Seres Therapeutics' Accumulated Expenses fell 63.98% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year decrease of 63.98%. This contributed to the annual value of $10.7 million for FY2024, which is 52.38% down from last year.
  • Seres Therapeutics' Accumulated Expenses amounted to $6.4 million in Q3 2025, which was up 9.86% from $5.8 million recorded in Q2 2025.
  • Seres Therapeutics' 5-year Accumulated Expenses high stood at $86.4 million for Q2 2024, and its period low was $5.8 million during Q2 2025.
  • Over the past 3 years, Seres Therapeutics' median Accumulated Expenses value was $22.5 million (recorded in 2023), while the average stood at $35.1 million.
  • As far as peak fluctuations go, Seres Therapeutics' Accumulated Expenses surged by 332.06% in 2021, and later tumbled by 93.27% in 2025.
  • Quarterly analysis of 5 years shows Seres Therapeutics' Accumulated Expenses stood at $45.1 million in 2021, then spiked by 32.70% to $59.8 million in 2022, then crashed by 62.38% to $22.5 million in 2023, then tumbled by 52.38% to $10.7 million in 2024, then crashed by 63.98% to $6.4 million in 2025.
  • Its Accumulated Expenses was $6.4 million in Q3 2025, compared to $5.8 million in Q2 2025 and $6.2 million in Q1 2025.